Novo Nordisk’s Dual Narrative: Promising Hemophilia Data and Steady Buybacks vs. a Glitch in the Obe
Novo Nordisk ended the week at €43.32, notching a 1.29% gain in Friday’s session. The move capped a…
Novo Nordisk’s Summer Rally Hinges on Buybacks, Data Readouts, and a Cybersecurity Shadow
The Danish drugmaker’s stock has clawed back nearly 40?% from its March trough, touching €42.19 in recent trading…
Novo Nordisk’s Rally Faces a Pivotal Week of Data, Buybacks, and Medicare Tailwinds
The Danish drugmaker’s stock has clawed back nearly 40% from its March trough of €30.25, closing last week…
Novo Nordisk Bets on Buybacks and Pipeline Data as Prescription Boom Meets Washington Pricing Pressu
Novo Nordisk’s oral obesity therapy drives 2M prescriptions in 5 months, but shares tumble 48% from peak amid…
Novo Nordisk’s Pipeline Verdict Looms as Wegovy’s Formulary Edge Crumbles and Buybacks Fall Shor
As commercial pressures mount from Lilly rivals and patent expiries, Novo Nordisk’s upcoming data readouts for CagriSema and…
Novo Nordisk Juggles Share Buybacks and Pipeline Hype as CagriSema Data Approaches
Danish pharma giant unveils REIMAGINE Phase 3 results for CagriSema, runs $1.6B buyback, as stock tumbles 39% amid…
Novo Nordisk Invests Billions in Buybacks While Expanding Heart-Disease Evidence
Novo Nordisk repurchases DKK 4.47bn in shares amid 38% stock drop, unveils POSEIDON study on residual inflammatory risk,…
Novo Nordisk Confronts a Squeeze From All Sides as Buybacks Meet a Pricing Onslaught
Novo Nordisk accelerates $4.2B buyback as stock trades near half 52-week high, while Trump administration expands TrumpRx with…
Buybacks, Greenland, and a Cash-Rich Paradox
European Lithium launches a share buyback amid Greenland regulatory bottleneck for its Tanbreez rare earths project. The firm…
Is It Still Cheap for US Investors?
Danske Bank just confirmed another hefty capital return, but the stock still trades at a discount to big…
Is It Still Cheap for US Investors?
Danske Bank just confirmed another hefty capital return, but the stock still trades at a discount to big…